Glecaprevir/Pibrentasvir Treatment in a Patient with Hemophilia and Mixed Genotype Hepatitis C Infection Mikst Tip Hepatit C Genotipine Sahip Hemofili Hastasının Glecaprevir + Pibrentasvir ile Tedavisi
Viral Hepatitis Journal, cilt.27, sa.3, ss.159-161, 2021 (ESCI, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 27 Sayı: 3
- Basım Tarihi: 2021
- Doi Numarası: 10.4274/vhd.galenos.2021.2021-1-5
- Dergi Adı: Viral Hepatitis Journal
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.159-161
- Anahtar Kelimeler: Antiviral drugs, hemophilia A, hepatitis C virus
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Patients who require frequent blood product transfusions, such as patients with hemophilia, are at risk of contracting hepatitis C virus (HCV). The prevalence of mixed HCV genotype infection is higher in this patient group. The patient presented here was a 22-year-old Afghan citizen who had received blood product transfusions since birth due to hemophilia A. He was found to have HCV infection during follow-up in the hematology clinic three years ago, and HCV genotypes 1b, 3, and 4 were detected. Treatment with glecaprevir/pibrentasvir was administered for 8 weeks. The patient reported no side-effects other than headache that resolved when treatment was discontinued. Transaminase values improved from pre-treatment level and were within normal limits at the end of the treatment. The patient showed sustained virologic response at 24 weeks. Pangenotypic direct-acting antivirals, which have just been included in the reimbursement scope in our country, have eliminated the difficulty in choosing drugs in this indication. Single drug administration has led to more successful patient outcomes by increasing treatment compliance.